300 results
6-K
EX-99.1
BNTX
BioNTech SE
21 May 24
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
4:36pm
, but not be limited to, statements concerning: the initiation, timing, progress and results of BioNTech’s research and development programs in oncology, including … to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion
6-K
EX-99.1
BNTX
BioNTech SE
17 May 24
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
4:10pm
to, statements concerning BioNTech’s financial position; BioNTech’s research and development programs, including statements characterizing timing
6-K
EX-99.2
BNTX
BioNTech SE
17 May 24
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
4:10pm
or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current … solutions; and BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital
6-K
EX-99.1
BNTX
BioNTech SE
6 May 24
Current report (foreign)
7:18am
€, except per share data)
Note
(unaudited)
Revenues
Cost of sales
Research and development expenses
Sales and marketing expenses
General … , 2024, take contractual compensation payments into consideration.
Research and Development Expenses
From the three months ended March 31, 2023
6-K
EX-99.2
BNTX
BioNTech SE
6 May 24
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
6:48am
or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future … ; and BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures
6-K
EX-99.1
y3fmf0shzx
6 May 24
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
6:48am
6-K
EX-99.1
9fp lkpel9l3fb
8 Apr 24
Invitation to the Annual General Meeting 2024
5:05pm
6-K
EX-99.1
z4ynk87wax 1h6mh
8 Apr 24
Current report (foreign)
7:12am
6-K
EX-99.1
k71m8tcmk769f4g2c5b
11 Mar 24
BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
9:04am
6-K
EX-99.1
pa6zrc21ykliee8onw5o
7 Mar 24
BioNTech Announces Planned Retirement of Sean Marett
8:41am
S-8
EX-4.1
ebh76hxmml
15 Feb 24
Registration of securities for employees
4:10pm
6-K
EX-99.1
ubuf1wddnwfr iotaqtx
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:08am
6-K
EX-99.1
8ijdsnihtyi6u2gl0
31 Jan 24
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
7:47am
6-K
EX-99.1
6h4pf
22 Jan 24
Current report (foreign)
9:14am
6-K
EX-99.2
h9ibf52c
9 Jan 24
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
7:01am
6-K
EX-99.1
vys44v7wy2mr5
9 Jan 24
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
7:01am
6-K
EX-99.1
uwe 6xsvd0f
21 Dec 23
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
4:02pm
6-K
EX-99.1
7pp7s4ib
18 Dec 23
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
4:22pm
6-K
EX-99.1
58hrcfukg7w 39
7 Dec 23
BioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem
8:17pm
6-K
EX-99.1
lmocuusw5xlfk
7 Nov 23
1 Welcome & Introductory Remarks Ryan Richardson Chief Strategy Officer
8:03am